Abstract
A new therapeutic agent for heart failure can be approved if it improves survival and/or reduces hospitalisations or if it safely improves functional capacity. Therefore its clinical development program must demonstrate clinically relevant improvement in a robust clinical end point and adequate safety to justify regulatory approval and clinical use. Mortality and hospitalisations are now combined with new composite end points in order to improve trial efficiency and adequate assessment of efficacy of newer molecules, biologicals and cell therapies developed for the treatment of heart failure. Newer regulatory practices have been developed in the past few years and they will require design of innovative study designs able to demonstrate a sound clinical benefit alongside with adequate safety profile.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F (2016) Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Eur J Heart Fail 18(5):482–489
Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O’Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M (2014) Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2(2):97–112
Capuano A, Coats AJ, Scavone C, Rossi F, Rosano GM (2015) Disclosure of negative trial results. A call for action. Int J Cardiol 198:47–48
Collins SP, Pang PS, Fonarow GC, Yancy CW, Bonow RO, Gheorghiade M (2013) Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing Hospitalization and reHospitalization. J Am Coll Cardiol 61:121–126
ESC Committee for Practice Guidelines (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2016: The task force for the diagnosis and treatment of acute and chronic heart failure 2016 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975
Fishbein DP, Hellkamp AS, Mark DB et al (2014) Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure trial). J Am Coll Cardiol 63:2560–2568
Gheorghiade M, Shah AN, Vaduganathan M, Butler J, Bonow RO, Rosano GM, Taylor S, Kupfer S, Misselwitz F, Sharma A, Fonarow GC (2013) Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Fail Clin 9(3):285–290. doi:10.1016/j.hfc.2013.05.002, v-vi
Greene SJ, Shah AN, Butler J, Ambrosy AP, Anker SD, Chioncel O, Collins SP, Dinh W, Dunnmon PM, Fonarow GC, Lam CS, Mentz RJ, Pieske B, Roessig L, Rosano GM, Sato N, Vaduganathan M, Gheorghiade M (2014) Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J 168(2):142–149
Harinstein ME, Butler J, Greene SJ, Fonarow GC, Stockbridge NL, O’Connor CM, Pfeffer MA, Mehra MR, Solomon SD, Yancy CW, Fiuzat M, Mentz RJ, Collins SP, McMurray JJ, Vaduganathan M, Dunnmon PM, Rosano GM, Dinh W, Misselwitz F, Bonow RO, Gheorghiade M (2015) Site selection for heart failure clinical trials in the USA. Heart Fail Rev 20(4):375–383
Pani L, Pecorelli S, Rosano G, Anker SD, Peracino A, Fregonese L, Prasad K, Rasi G (2015) Steps forward in regulatory pathways for acute and chronic heart failure. Eur J Heart Fail 17(1):3–8
Pelliccia F, Rosano GM (2015) Back to the future: the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure. Eur Heart J Cardiovasc Pharmacother 1(1):37–38
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36(11):657–668. doi:10.1093/eurheartj/ehu385
Rosano GM, Anker SD, Marrocco W, Coats AJ (2015) Adaptive licensing - a way forward in the approval process of new therapeutic agents in Europe. Int J Cardiol 184:568–569
Schüssler-Lenz M, Beuneu C, Menezes-Ferreira M, Jekerle V, Bartunek J, Chamuleau S, Celis P, Doevendans P, O’Donovan M, Hill J, Hystad M, Jovinge S, Kyselovič J, Lipnik-Stangelj M, Maciulaitis R, Prasad K, Samuel A, Tenhunen O, Tonn T, Rosano G, Zeiher A, Salmikangas P (2016) Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. Eur J Heart Fail 18(2):133–141
Seltzer JH, Turner JR, Geiger MJ, Rosano G, Mahaffey KW, White WB, Sabol MB, Stockbridge N, Sager PT (2015) Centralized adjudication of cardiovascular endpoints in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. Am Heart J 169(2):197–204
Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J (2013) The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 10:85–97
Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ (2013) Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 15(10):1082–1094
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Rosano, G.M.C. (2016). Clinical Trial Design, Endpoints, and Regulatory Requirements. In: Bauersachs, J., Butler, J., Sandner, P. (eds) Heart Failure. Handbook of Experimental Pharmacology, vol 243. Springer, Cham. https://doi.org/10.1007/164_2016_75
Download citation
DOI: https://doi.org/10.1007/164_2016_75
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59658-7
Online ISBN: 978-3-319-59659-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)